DRREDDYBSEDr Reddys Laboratories LtdLowNeutral
Announced Sat, 30 May · 13:03 IST

Dr. Reddy''s Laboratories Limited has informed the Exchange that the Annual Report in Form 20F for the fiscal year ended March 31, 2026 has been filed with United States Securities and ....

DRREDDY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.3%1-day move
₹1320.00
prior close
₹1310.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1-0.2-0.7-0.5-3.3-4.4-3.9-2.8-3.4-3.6-2.1+1.4
Up moveDown movePending
AI summary

Dr. Reddy's Laboratories has informed exchanges that its Annual Report in Form 20-F for fiscal year ended March 31, 2026 was filed with the US Securities and Exchange Commission on May 30, 2026. The report contains annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. The company is listed on NSE (DRREDDY), BSE (500124), NYSE (RDY), and NSE IFSC Ltd. This disclosure is made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Likely market impact

This is a routine regulatory compliance filing confirming the company has met its statutory reporting requirements with both Indian and US regulators. The filing indicates normal operational progress with no material deviations from expected disclosure timelines. Shareholders on all exchanges can now access the comprehensive annual report.